Regulatory News:
Sanofi and Roche Diabetes Care France - two leaders convinced of
the added value of new technologies for better management and
personalized support of patients with diabetes - have joined forces
regarding the smart device Mallya® for SoloStar developed by
Biocorp (Paris:ALCOR) - a French company specializing in the
development and manufacture of medical devices and injectable drug
delivery systems. Mallya® for SoloStar is the only CE Class IIb
medical device for insulin injection pens that is compatible with
all SoloStar® insulin pens.
Sanofi and Roche Diabetes Care France have a long history of
developing solutions that link insulins, medical devices, and
digital solutions. Sanofi's teams are constantly pursuing insulin
development programs by generating real-life data on their use to
improve their proper use and efficiency.
Roche Diabetes Care France teams are designing devices and
applications so that people with diabetes need not think about the
daily management of their disease. Through this partnership, the
two companies intend to contribute together to the safety and
comfort of people with diabetes through a connected ecosystem.
Mallya for SoloStar®, a connected device that facilitates
diabetes management
Managing diabetes is challenging for patients taking insulin:
frequent blood glucose monitoring, adjusting the dose of insulin to
be injected and recording injection data in the blood glucose
logbook. This information is necessary for proper management and
provides a basis for discussion with the healthcare professional.
The time spent collecting this information for the proper
monitoring of the disease can affect the daily life of diabetic
patients. Therefore, it is important to provide them with solutions
to simplify their lives.
To meet these challenges and improve patients' daily lives,
Sanofi and Roche Diabetes Care France are mobilizing to make the
Mallya connected device for SoloStar® known and adopted by the
greatest number of patients and healthcare professionals. Mallya
for SoloStar® automatically collects, in real time, the insulin
doses selected by the patient during the day. Mallya for SoloStar®
is part of a comprehensive and personalized diabetes management
system, made possible by the connection with Accu-Chek® blood
glucose meters, the Gluci Chek mobile application and the Roche
Diabetes Care Platform dedicated to healthcare professionals.
Patients can view their injection history, track their blood
glucose results, and share this data with their healthcare team.
Thus, healthcare professionals can access complete and accurate
data on both insulin and glycemia, for a close and individualized
follow-up of patients on insulin. The Mallya device for Solostar®
is compatible with the various Sanofi insulins presented in
SoloStar® pre-filled pens, including Toujeo®, Apidra® and Insulin
Asparte Sanofi®.
“Despite existing treatments and solutions, the prevalence of
diabetes continues to rise, and many patients with diabetes do not
reach the glycemic target set by their physician. At Sanofi, we are
convinced that only a global approach to the day-to-day management
of patients will improve their care. Therefore, we have chosen to
invest in solutions to improve compliance and better personalize
the management of each patient. The development of a connected
ecosystem, based on innovative and easy-to-use technologies, should
encourage the adoption of sustainable health habits and improve
clinical outcomes for patients with diabetes," said Hubert de Ruty,
Chief Executive Officer at Sanofi France.
A unique partnership between two major players in diabetes
management
According to the terms of the partnership, Roche Diabetes Care
France and Sanofi have committed to jointly deploy a scientific
program for physicians and retail pharmacists around the Mallya
connected ecosystem for SoloStar® and diabetes management.
"We are convinced of the relevance of digital solutions in the
management of patients with diabetes. To share this point of view
with doctors and pharmacists, Roche and Sanofi will organize in the
coming months a dozen physical and virtual events on the theme
"Insulin therapy & connected ecosystem for the benefit of type
2 diabetes patients", Frédéric Jacquey, President, Roche Diabetes
Care France.
Éric Dessertenne, CEO of Biocorp: "We are delighted to see two
of our partners join forces to promote and accelerate the adoption
of our connected device in France. This unprecedented alliance
validates the commitment of the largest pharmaceutical groups to
the digitalization of diabetes, which contributes to better patient
care and monitoring. The proliferation of digital health
applications and devices is a major trend in our industry, as
evidenced by the recent announcement by French President Emmanuel
Macron of his desire to make digital therapeutic apps available on
prescription through the healthcare system.”
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
About Roche Diabetes Care
Roche Diabetes Care is a healthcare company specializing in
diabetes. For over 40 years, it has been developing medical
devices, digital solutions, and services to meet the needs of
patients and healthcare professionals. Thanks to its global
solution connecting medical devices and digital solutions, Roche
Diabetes Care opens the way to personalized diabetes management,
with the ambition of facilitating and optimizing the management and
monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in
France, alongside Roche SAS France and Roche Diagnostics France.
For more information, please visit www.roche.fr
Roche Diabetes Care France, 2 avenue du Vercors 38240 Meylan
Roche Diabetes Care Platform is an online solution for
collecting and visualizing blood glucose data for healthcare
professionals to facilitate the monitoring of diabetic patients. -
Manufacturer: Roche Diabetes Care GmbH (Germany) - Distributor:
Roche Diabetes Care France
This medical device is a regulated health product and bears the
CE mark. Please read the instructions carefully.
Self-monitoring of blood glucose is used when it is likely to
lead to a change in therapy; it must be systematic and repeated
daily in type 1 diabetes and limited to certain patients in type 2
diabetes. It requires education with a health professional. In case
of discrepancy between the result and your current state of health,
contact your health professional.
About Biocorp
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 70 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR).
For more information, please visit www.biocorpsys.com.
Mallya® is a medical device for wireless collection and transfer
of insulin pen dose data. - Manufacturer: Biocorp Production -
Distributor: Roche Diabetes Care France. This medical device is a
regulated health product which bears, under this regulation, the CE
mark. Read carefully the instructions. November 2021. FR-2127
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211103006350/en/
Press Contacts Sanofi Chrystel Baude
chrystel.baude@sanofi.com +33 (0)1 57 63 25 04 Roche Diabetes
Care France Raphaële Badel raphaele.badel@roche.com +33 (0)7 77
34 60 59 BIOCORP Sylvaine Dessard rp@biocorp.fr + 33 (0)6 88
69 72 85 Springbok Consultants Marina Rosoff
marine@springbok.fr + 33 (0)6 71 58 00 34 Havas Paris Myriam
Hamza rochediabpresse@havas.com +33 (0)6 45 87 46 51 ULYSSE
COMMUNICATION Bruno Arabian barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Nov 2023 bis Dez 2023
Biocorp (EU:ALCOR)
Historical Stock Chart
Von Dez 2022 bis Dez 2023
